Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
Status: Enrolling
Updated:  1/31/2011
The University of Texas Health Science Center at Houston
mi
from
Houston, TX
Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
Status: Enrolling
Updated: 1/31/2011
The University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/31/2011
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/31/2011
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Coreg CR, Blood Vessel Stiffness and Blood Vessel Function
Effect of Coreg CR on BP, Endothelial Function, Exhaled Nitric Oxide, and Nitric Oxide Production and Oxidation
Status: Enrolling
Updated:  2/9/2011
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Coreg CR, Blood Vessel Stiffness and Blood Vessel Function
Effect of Coreg CR on BP, Endothelial Function, Exhaled Nitric Oxide, and Nitric Oxide Production and Oxidation
Status: Enrolling
Updated: 2/9/2011
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/25/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/25/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy and Safety of Fibrin Sealant (FS) VH S/D-APR for Hemostasis and Wound Healing in Endoscopic Browlift
A Randomized, Controlled Study to Evaluate Safety and Efficacy of Fibrin Sealant VH S/D 4 S-APR (Artiss) for Tissue Adherence and Hemostasis and To Improve Wound Healing in Subjects Undergoing Endoscopic Browlift
Status: Enrolling
Updated:  3/19/2011
Davis B Nguyen, M.D.
mi
from
Beverly Hills, CA
Efficacy and Safety of Fibrin Sealant (FS) VH S/D-APR for Hemostasis and Wound Healing in Endoscopic Browlift
A Randomized, Controlled Study to Evaluate Safety and Efficacy of Fibrin Sealant VH S/D 4 S-APR (Artiss) for Tissue Adherence and Hemostasis and To Improve Wound Healing in Subjects Undergoing Endoscopic Browlift
Status: Enrolling
Updated: 3/19/2011
Davis B Nguyen, M.D.
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia
Status: Enrolling
Updated:  3/21/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia
Status: Enrolling
Updated: 3/21/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
Status: Enrolling
Updated:  4/18/2011
Weill-Cornell Medical College
mi
from
New York, NY
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
Status: Enrolling
Updated: 4/18/2011
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Front Range Cancer Specialists
mi
from
Loveland, CO
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Front Range Cancer Specialists
mi
from
Loveland, CO
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
U T M D Anderson Cancer Center
mi
from
Houston, TX
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
U T M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Kettering, OH
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Oregon Health and Science University
mi
from
Portland, OR
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Springfield, OR
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Springfield, OR
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Greenville, SC
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Norfolk, VA
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Yakima, WA
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Yakima, WA
Click here to add this to my saved trials
Study to Determine the Accuracy of Prothrombin Time of Warfarinised Blood
Mobius PT-INR Accuracy Clinical Study
Status: Enrolling
Updated:  6/16/2011
White River Diagnostic Clinic
mi
from
Batesville, AR
Study to Determine the Accuracy of Prothrombin Time of Warfarinised Blood
Mobius PT-INR Accuracy Clinical Study
Status: Enrolling
Updated: 6/16/2011
White River Diagnostic Clinic
mi
from
Batesville, AR
Click here to add this to my saved trials
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates
Status: Enrolling
Updated:  7/19/2011
Massachusetts General Hospital
mi
from
Boston, MA
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates
Status: Enrolling
Updated: 7/19/2011
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.
Status: Enrolling
Updated:  7/19/2011
Saint Louis University
mi
from
St. Louis, MO
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.
Status: Enrolling
Updated: 7/19/2011
Saint Louis University
mi
from
St. Louis, MO
Click here to add this to my saved trials
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.
Status: Enrolling
Updated:  7/19/2011
University of Utah Health Sciences Centre
mi
from
Salt Lake City, UT
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.
Status: Enrolling
Updated: 7/19/2011
University of Utah Health Sciences Centre
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Omega 3 Supplementation for the Prevention of Disease Progression in Early Stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies
Status: Enrolling
Updated:  7/29/2011
Edwards Comprehensive Cancer Center
mi
from
Huntington, WV
Omega 3 Supplementation for the Prevention of Disease Progression in Early Stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies
Status: Enrolling
Updated: 7/29/2011
Edwards Comprehensive Cancer Center
mi
from
Huntington, WV
Click here to add this to my saved trials
Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)
Status: Enrolling
Updated:  8/2/2011
St. John Hospital and Medical Center
mi
from
Grosse Pointe, MI
Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)
Status: Enrolling
Updated: 8/2/2011
St. John Hospital and Medical Center
mi
from
Grosse Pointe, MI
Click here to add this to my saved trials
Radioimmunoimaging of AL Amyloidosis
Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4
Status: Enrolling
Updated:  8/3/2011
University of Tennessee Medical Center
mi
from
Knoxville, TN
Radioimmunoimaging of AL Amyloidosis
Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4
Status: Enrolling
Updated: 8/3/2011
University of Tennessee Medical Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
Multicenter Blood Culture Quality Improvement
Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department
Status: Enrolling
Updated:  8/9/2011
Vanderbilt Emergency Medicine
mi
from
Nashville, TN
Multicenter Blood Culture Quality Improvement
Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department
Status: Enrolling
Updated: 8/9/2011
Vanderbilt Emergency Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
Multicenter Blood Culture Quality Improvement
Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department
Status: Enrolling
Updated:  8/9/2011
Vanderbilt University Medical Center - Emergency Medicine
mi
from
Nashville, TN
Multicenter Blood Culture Quality Improvement
Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department
Status: Enrolling
Updated: 8/9/2011
Vanderbilt University Medical Center - Emergency Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Tulane University
mi
from
New Orleans, LA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Johns Hopkins Hospital
mi
from
Baltimore, MD
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
University of Maryland
mi
from
Baltimore, MD
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Children's Hospital - Boston
mi
from
Boston, MA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Brigham and Women's Hosp
mi
from
Boston, MA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Massachusetts General Hospital
mi
from
Boston, MA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Weill Medical College of Cornell University
mi
from
New York, NY
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Duke University
mi
from
Durham, NC
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Case Western Reserve Univ
mi
from
Cleveland, OH
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
The University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
The University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Univ of Pennsylvania
mi
from
Philadelphia, PA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
University of Pittsburgh Presbyterian and Shadyside Hospital
mi
from
Pittsburgh, PA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
University of Pittsburgh Presbyterian and Shadyside Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
University of Washington Medical Center
mi
from
Seattle, WA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Gundersen Clinic
mi
from
LaCrosse, WI
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Gundersen Clinic
mi
from
LaCrosse, WI
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
University of Wisconsin
mi
from
Madison, WI
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML
Status: Enrolling
Updated:  9/19/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML
Status: Enrolling
Updated: 9/19/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection
Status: Enrolling
Updated:  9/26/2011
Mount Sinai School of Medicine
mi
from
New York, NY
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection
Status: Enrolling
Updated: 9/26/2011
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Oral Clofarabine for Acute Myeloid Leukemia
Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
Status: Enrolling
Updated:  10/6/2011
Washington University
mi
from
St. Louis, MO
Oral Clofarabine for Acute Myeloid Leukemia
Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
Status: Enrolling
Updated: 10/6/2011
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases
Status: Enrolling
Updated:  10/18/2011
Columbia University Medical Center
mi
from
New York, NY
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases
Status: Enrolling
Updated: 10/18/2011
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With the AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Multiple Myeloma
Status: Archived
Updated:  11/17/2011
GSK Investigational Site
mi
from
Austin, TX
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With the AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Multiple Myeloma
Status: Archived
Updated: 11/17/2011
GSK Investigational Site
mi
from
Austin, TX
Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery
Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Elective Cesarean Delivery.
Status: Enrolling
Updated:  1/13/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery
Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Elective Cesarean Delivery.
Status: Enrolling
Updated: 1/13/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials